Clinical Trial Update: Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating abiraterone acetate plus prednisone with or without dasatinib for metastatic castration-resistant prostate cancer; the updat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• DASATINIB (Dasatinib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: University of Southern California | Conditions: Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: UNKNOWN